SCHEMBL18709358

SCHEMBL18709358

O=C(Nc1ccc(S(=O)(=O)NC2CCOC2=O)cc1)c1ccc(Br)o1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 6/20 0.67
▸ HPGD P15428 5/20 0.67
▸ HSD17B10 Q99714 7/20 0.53
▸ ALDH1A1 P00352 6/20 0.53
▸ SMN1; SMN2 Q16637 5/20 0.53
▸ HTT P42858 4/20 0.53
▸ MAPK1 P28482 3/20 0.53
▸ L3MBTL1 Q9Y468 1/20 0.53
▸ MAPT P10636 8/20 0.53
▸ MEN1 O00255 7/20 0.53
▸ KMT2A Q03164 7/20 0.53
▸ KDM4E B2RXH2 4/20 0.53
▸ ALOX15 P16050 3/20 0.53
▸ USP2 O75604 2/20 0.52
▸ TP53 P04637 2/20 0.52
▸ NPSR1 Q6W5P4 1/20 0.52
▸ POLB P06746 3/20 0.50
▸ TSHR P16473 2/20 0.50
▸ CYP3A4 P08684 1/20 0.49
▸ CYP2C9 P11712 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20296959 1.00 LMNA (0.67) LMNAHPGDHSD17B10ALDH1A1SMN1; SMN2
SCHEMBL18687092 0.85 LMNA (0.48) LMNAHPGDHSD17B10ALDH1A1SMN1; SMN2
SCHEMBL18709362 0.85 LMNA (0.48) LMNAHPGDHSD17B10ALDH1A1SMN1; SMN2
SCHEMBL20296955 0.85 DDIT3 (0.61) MAPTKMT2ARAB9ANPC1
SCHEMBL18709397 0.85 DDIT3 (0.61) MAPTKMT2ARAB9ANPC1
SCHEMBL17329224 0.83 MEN1 (0.47) LMNAHPGDHSD17B10ALDH1A1SMN1; SMN2
SCHEMBL17329223 0.83 MEN1 (0.47) LMNAHPGDHSD17B10ALDH1A1SMN1; SMN2
SCHEMBL18687078 0.82 LMNA (0.66) LMNAHPGDALDH1A1SMN1; SMN2HTT
SCHEMBL18687079 0.82 LMNA (0.66) LMNAHPGDALDH1A1SMN1; SMN2HTT
SCHEMBL17329183 0.80 PRMT1 (0.52) LMNAHPGDALDH1A1L3MBTL1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10071994-B2 N-sulfonyl homoserine lactone derivatives, preparation method and use thereof INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY ACADEMY OF MILITARY MEDICAL SCIENCES P.L.A. CHINA (CN) 2018-09-11 — — US claimed
US-20180179193-A1 N-Sulfonyl Homoserine Lactone Derivatives, Preparation Method and Use Thereof INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY ACADEMY OF MILITARY MEDICAL SCIENCES P.L.A. CHINA (CN) 2018-06-28 — — US claimed
US-10071994-B2 N-sulfonyl homoserine lactone derivatives, preparation method and use thereof INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY ACADEMY OF MILITARY MEDICAL SCIENCES P.L.A. CHINA (CN) 2018-09-11 — — US disclosed
US-20180179193-A1 N-Sulfonyl Homoserine Lactone Derivatives, Preparation Method and Use Thereof INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY ACADEMY OF MILITARY MEDICAL SCIENCES P.L.A. CHINA (CN) 2018-06-28 — — US disclosed
US-20180179193-A1 N-Sulfonyl Homoserine Lactone Derivatives, Preparation Method and Use Thereof INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY ACADEMY OF MILITARY MEDICAL SCIENCES P.L.A. CHINA (CN) 2018-06-28 — — US disclosed
EP-3150594-A1 N-SULFONYL HOMOSERINE LACTONE DERIVATIVES, PREPARATION METHOD THEREFOR AND USE Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. China (CN) 2017-04-05 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180179193-A1 N-Sulfonyl Homoserine Lactone Derivatives, Preparation Method and Use Thereof LSS, SOS1, STS LMNA 1575/4885HPGD 640/4885HSD17B10 688/4885
US-10071994-B2 N-sulfonyl homoserine lactone derivatives, preparation method and use thereof LSS, SOS1, STS LMNA 1447/4885HPGD 685/4885HSD17B10 621/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback